Thymoquinone and its derivatives against breast cancer with HER2 positive: studies of ADMET, docking and QSPR.

Advanced Search

Adinda Adelia Wulandari, Achmad Aziz Choiri, Tri Widiandani

Author Information

Adinda Adelia Wulandari: Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia.
Achmad Aziz Choiri: Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia.
Fitria: Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia.
Tri Widiandani: Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia. ORCID

PMID: 34214298 DOI: 10.1515/jbcpp-2020-0431

OBJECTIVES: The high prevalence of HER2-positive breast cancer has become a significant concern in the health sector. The problem is more complex with the side effects of breast cancer drugs currently used. Thymoquinone (TQ), the main bioactive compound in , has been shown to have anticancer activity. However, it is necessary to modify the structure of the thymoquinone derivatives to improve drug bioavailability. This study uses an approach to predict pharmacokinetic profile, docking, quantitative structure-properties relationship (QSPR) of new thymoquinone-derived compounds as candidates cytotoxic agent for breast cancer with HER-2 positive.
METHODS: The prediction of ADMET was using pkCSM online. Molecular docking was used to determine thymoquinone derivatives activity using Molegro Virtual Docker version 5.5 by docking the thymoquinone derivatives to the HER2 receptor targets, PDB ID 3PP0 and QSPR analysis using the IBM SPSS 21 version.
RESULTS: The 35 thymoquinone derivatives showed good physicochemical and absorption properties and not hepatotoxic, so they are suitable for oral drugs. The molecular docking of 35 thymoquinone derivatives against 3PP0 proteins showed better activity than thymoquinone. One of the thymoquinone derivatives, TQ 15, showed the largest negative RS value, meaning that is predicted to have the highest anticancer activity. Based on the QSPR analysis, the essential parameter in determining 35 thymoquinone derivatives activity was the lipophilic and steric parameter.
CONCLUSIONS: Based on test, thymoquinone derivative, TQ 15, had the potential to be further developed as a HER2-positive breast cancer drug.

Molegro Virtual Docker QSPR breast cancer HER2 pkCSM thymoquinone

Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Canc J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492.

International Agency for Research on Cancer. GLOBOCAN 2018: Indonesia. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf [Accessed 5 Aug 2020].

Kordestani, LA, Blumental, GM, Xu, QC. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Canc Res 2014;20:4436–41.

Oakman, C, Pestrin, M, Zafarana, E, Cantisani, E, Leo, AD. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Canc Manag Res 2010;2:13–25. https://doi.org/10.3390/cancers2021221.

Moggs, J, Moullin, P, Pognan, F, Brees, D, Leonard, M, Busch, S. Investigative safety science as a competitive advantage for pharma. Expet Opin Drug Metabol Toxicol 2012;8:1071–82. https://doi.org/10.1517/17425255.2012.693914.

Breslin, S, Lowry, MC, O’Driscoll, L. Neratinib resistance and cross-resistance to other HER2-targetted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Canc 2017;116:620–5. https://doi.org/10.1038/bjc.2016.445.

Veeresham, C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res 2012;3:200–1. https://doi.org/10.4103/2231-4040.104709.

Abukhader, MM. Thymoquinone in the clinical treatment of cancer: fact or fiction? Phcog Rev 2013;7:117–20. https://doi.org/10.4103/0973-7847.120509.

Agbaria, R, Gabarin, A, Dahan, A, Ben-Shabat, S. Anticancer activity of Nigella sativa (black seed) and its relationship with the thermal processing and quinone composition of the seed. Drug Des Dev Ther 2015;9:3119–24. https://doi.org/10.2147/DDDT.S82938.

Khan, MA, Tania, M, Fu, S, Fu, J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget 2017;8:51907–19. https://doi.org/10.18632/oncotarget.17206.

Alkharfy, KM, Ahmad, A, Khan, RMA, Al-Shagha, W. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet 2015;40:319–23. https://doi.org/10.1007/s13318-014-0207-8.

Yao, H, Liu, J, Xu, S, Zhu, Z, Xu, J. The structural modification of natural products for novel drug discovery. Expet Opin Drug Discov 2017;2:121–40. https://doi.org/10.1080/17460441.2016.1272757.

Abdelazeem, AH, Mohamed, YMA, Gouda, AM, Omar, HA, Al Robaian, MM. Novel thymohydroquinone derivatives as potential anticancer agents: design, synthesis, and biological screening. Aust J Chem 2016;69:1277. https://doi.org/10.1071/CH16102.

Aertgeerts, K, Skene, R, Yano, J, Sang, BC, Zou, H, Snell, G, et al.. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011;286:18756–65. https://doi.org/10.1074/jbc.m110.206193.

Warren, GL, Do, TD, Kelley, BP, Nicholls, A, Warren, SD. Essential considerations for using protein-ligand structures in drug discovery. Drug Discov Today 2012;17:1270–81. https://doi.org/10.1016/j.drudis.2012.06.011.

Widiandani, T, Siswandono, S, Meiyanto, E. Anticancer evaluation of N-benzoyl-3-allylthiourea as potential antibreast cancer agent through enhances HER2 expression. J Adv Pharm Technol Res 2020;11:163–8. https://doi.org/10.4103/japtr.JAPTR_77_20.

Pires, DEV, Blundell, TL, Ascher, DB. pkCSM: predicting small molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066–72. https://doi.org/10.1021/acs.jmedchem.5b00104.

Doak, BC, Over, B, Girodanetto, F, Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol 2014;21:1115–42. https://doi.org/10.1016/j.chembiol.2014.08.013.

Nofianti, KA, Ekowati, J. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y 12 receptors. J Basic Clin Physiol Pharmacol 2019;30:1–14. https://doi.org/10.1515/jbcpp-2019-0327.

Hardjono, S, Widiandani, T, Purwanto, BT, Nasyanka, AL. Molecular docking of N-benzoyl-N′-(4-fluorophenyl) thiourea derivatives as anticancer drug candidate and their ADMET prediction. Res J Pharm Technol 2019;12:2160–6. https://doi.org/10.5958/0974-360x.2019.00359.7.

Widiandani, T, Siswandono, S, Meiyanto, E. Docking and antiproliferative effect of 4-T-butylbenzoyl-3-allylthiourea on MCF-7 breast cancer cells with/without HER-2 overexpression. In: Proceedings of International Conference on Applied Pharmaceutical Sciences (ICoAPS); 2018:69–73 pp.

Antineoplastic Agents

Benzoquinones

Computer Simulation

Molecular Docking Simulation

Neoplasms

Pharmaceutical Preparations

Antineoplastic Agents

Benzoquinones

Pharmaceutical Preparations

thymoquinone

Journal Article

OpenLB
Open Library of Bioscience